Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in Germany
ConclusionsGolimumab is an effective treatment in patients with RA, PsA, and AS, irrespective of any pretreatment with biologic agents.Study RegistrationClinicalTrials.gov NCT01313858.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research
More News: Ankylosing Spondylitis | Arthritis | Clinical Trials | Germany Health | Psoriatic Arthritis | Rheumatoid Arthritis | Rheumatology | Study